Tracer library / [89Zr]DFO-11E10C11

[89Zr]DFO-11E10C11

Also written as [Zr-89]Zr-DFO-11E10C11

Radionuclide: Zr-89 t½ 4704 min
Modality: PET
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Breast cancer Preclinical only, no clinical indication yet Receptor expression phenotyping

What it is

Compound class: DFO-conjugated anti-CDH3 monoclonal antibody
Target / mechanism: CDH3 (P-cadherin) targeting via anti-CDH3 monoclonal antibody 11E10C11 PMID 41570246
Clinical application: Triple-negative breast cancer (TNBC) PMID 41570246
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	>99%	>99%	DFO-11E10C11	41570246 2026 Mol Pharm A solution of 89Zr(IV) oxalate ... was adjusted to pH 7.0 using 0.5 M Na2CO3 ... CDH3-DFO conjugate was then added at a 1:2 molar ratio ... incubated at 37 °C in a metal bath for 90 min - TLC analysis demonstrated labeling yields >99% for both radiolabeled conjugates

Need this precursor?We can point you to suppliers for [89Zr]DFO-11E10C11, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41570246. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41570246: 'Synthesis of DFO-11E10C11'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Zr-89 is a positron emitter used only for PET imaging. Linked articles: PMID 41570246. Stage set/updated at stage 39 from PMID 41570246: 'Preclinical Study of CDH3-Targeted 89Zr/177Lu Theranostics in Triple-Negative Breast Cancer.'.